NanoPalm
NanoPalm is a DeepTech-Bio company revolutionizing in-vivo therapies for genetic diseases. They utilize an advanced Lipid Nanoparticle (LNP) manufacturing process powered by a proprietary AI platform, EnsaliX, to create stable LNPs capable of self-targeting specific organs and cells, overcoming the limitations of current LNP-based therapies. Their vision is to cure genetic diseases globally by developing new nanomedicines that offer superior patient experiences through personalized and effective treatments. The company leverages deep neural networks for affordable R&D and high safety profiles, deep nanotechnology for accelerated R&D and custom nanoformulations, and deep lipid assembly for effective, attractive, and innovative clinical trials with organ self-targeting capabilities. NanoPalm has developed two key product lines: Cochleate BioRobot, proprietary lipid-based nanoparticles for oral delivery of RNA and DNA, and DLC BioRobot, which enables nucleic acid delivery directly into 3D matrices. They also offer Cell Specific BioRobots for targeted therapy delivery. NanoPalm was selected for Charles River Laboratories' inaugural Advanced Therapy Incubator Program (CIP), highlighting their progress in AI-optimized LNPs for gene therapy.
NanoPalm
NanoPalm is a DeepTech-Bio company revolutionizing in-vivo therapies for genetic diseases. They utilize an advanced Lipid Nanoparticle (LNP) manufacturing process powered by a proprietary AI platform, EnsaliX, to create stable LNPs capable of self-targeting specific organs and cells, overcoming the limitations of current LNP-based therapies. Their vision is to cure genetic diseases globally by developing new nanomedicines that offer superior patient experiences through personalized and effective treatments. The company leverages deep neural networks for affordable R&D and high safety profiles, deep nanotechnology for accelerated R&D and custom nanoformulations, and deep lipid assembly for effective, attractive, and innovative clinical trials with organ self-targeting capabilities. NanoPalm has developed two key product lines: Cochleate BioRobot, proprietary lipid-based nanoparticles for oral delivery of RNA and DNA, and DLC BioRobot, which enables nucleic acid delivery directly into 3D matrices. They also offer Cell Specific BioRobots for targeted therapy delivery. NanoPalm was selected for Charles River Laboratories' inaugural Advanced Therapy Incubator Program (CIP), highlighting their progress in AI-optimized LNPs for gene therapy.